Globus Medical Q2 Earnings Call Highlights
Globus Medical (GMED) reported Q2 results on an earnings call. International spine revenue rose 12% constant-currency. Trauma revenue grew 31% YoY and 18% sequentially. Enabling Technologies revenue fell 26% YoY to $26.1M, while Excelsius placements rose. Nevro revenue declined 14.3% YoY. GAAP gross margin was 66.8%. GMED raised 2026 non-GAAP EPS to $4.95-$5.05 and reaffirmed revenue guidance of $3.18-$3.22B.
How this was made
The 30-second read
Why it matters
Traders can update positioning based on the raised full-year non-GAAP EPS range, reiterated revenue guidance, improved gross margins, and specific timing for the SCRIPT product launch in Q3, while monitoring execution risk around the capital-acquisition transition and Nevro trial-volume recovery.
Market read
A guidance and margin update with concrete product-launch timing and integration milestones, likely driving near-term sentiment and positioning for medtech/spine exposure.
What to watch
Gross margin expansion was partly attributed to merger-related synergies and manufacturing/supply-chain initiatives; if these benefits fade, the raised EPS range may be harder to sustain.
Background
The piece summarizes Globus Medical’s Q2 earnings call, covering spine and trauma growth, enabling-technologies strategy, Nevro integration, margin performance, and 2026 guidance.
Ticker impact
Globus Medical raised 2026 non-GAAP EPS to $4.95 to $5.05 and reiterated 2026 revenue guidance, alongside margin expansion and product launch timing.
Bias modestly positive for the next few sessions, with upside capped by stated execution risks in enabling-technology and Nevro recovery.
The article contains multiple fresh guidance and margin datapoints plus specific third-quarter launch timing, which typically supports re-rating, while the company’s own caution on the second half can limit follow-through.
Market effects
Signals improving profitability in spine/orthopedics devices and continued traction in robotic navigation usage, potentially supporting sentiment for medtech peers.
Highlights mid-teens growth in Italy, Spain, Poland and broad-based Asia-Pacific growth, which may influence regional demand expectations for spine procedures.
Reinforces global demand durability for musculoskeletal solutions and the ongoing shift toward equipment-as-a-service models.
Counterpoint
The enabling-technologies revenue decline and lack of separate Nevro outlook could mean near-term earnings quality is more dependent on cost synergies than underlying demand.
Key entities
- companyGlobus Medical, Inc.
NYSE-listed medical device maker focused on spine and orthopedics; reported Q2 segment performance and updated 2026 EPS and margin expectations.
- acquired business unitNevro
Pain-management business acquired in 2025; integration progress and trial-volume recovery were discussed without separate 2026 outlook.
- robotic technologyExcelsiusGPS and ExcelsiusHub
Robotic units used for procedures; placements rose sequentially and year over year per management commentary.
- product launchSCRIPT lumbar spacers and rods
Patient-specific products expected to launch later in Q3, integrating with Excelsius technology platform.
